永顺生物
(839729)
| 流通市值：4.89亿 | | | 总市值：16.65亿 |
| 流通股本：8024.46万 | | | 总股本：2.73亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 205,984,757.13 | 161,395,328.66 | 244,810,339.41 | 196,981,213.43 |
| 应收票据及应收账款 | 107,977,565.45 | 116,017,831.12 | 153,702,928.09 | 126,211,742.16 |
| 其中：应收票据 | 13,408,415.33 | 14,613,285.7 | 25,509,909.3 | 17,883,870.5 |
| 应收账款 | 94,569,150.12 | 101,404,545.42 | 128,193,018.79 | 108,327,871.66 |
| 应收款项融资 | 3,283,790 | 3,283,790 | - | - |
| 预付款项 | 186,862.42 | 862,322 | 434,813.75 | 442,541.71 |
| 其他应收款合计 | 2,124,299.08 | 1,888,780.12 | 2,235,656.75 | 2,458,857.07 |
| 存货 | 41,366,432.72 | 41,281,158.78 | 33,830,706.15 | 46,768,522.47 |
| 其他流动资产 | 203,369,520.26 | 202,086,913.62 | 157,686,677.93 | 177,658,677.74 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 584,482,912.07 | 563,546,980.74 | 613,010,371.44 | 581,132,813.12 |
| 非流动资产: | | | | |
| 其他非流动金融资产 | 150,000 | 150,000 | 150,000 | 150,000 |
| 固定资产 | 187,963,269.75 | 193,992,689.95 | 199,883,705.7 | 206,848,359.99 |
| 在建工程 | 7,403,231.84 | 8,039,471.84 | 340,816.84 | 340,816.84 |
| 使用权资产 | 1,424,152.88 | 1,562,358.26 | 1,656,822.04 | 1,791,957.82 |
| 无形资产 | 5,253,700.02 | 5,386,250.01 | 5,602,133.14 | 4,086,149.64 |
| 长期待摊费用 | 369,824.42 | 405,613.91 | 441,403.4 | 477,192.89 |
| 其他非流动资产 | 14,818,917.25 | 14,776,600 | 21,469,182.25 | 22,524,432.25 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 217,383,096.16 | 224,312,983.97 | 229,544,063.37 | 236,218,909.43 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 801,866,008.23 | 787,859,964.71 | 842,554,434.81 | 817,351,722.55 |
| 流动负债: | | | | |
| 短期借款 | 27,388,015.75 | 19,401,038.96 | 74,873,754.43 | 65,048,750 |
| 应付票据及应付账款 | 56,307,418.7 | 46,539,069.87 | 50,637,571.41 | 49,710,896.85 |
| 应付账款 | 56,307,418.7 | 46,539,069.87 | 50,637,571.41 | 49,710,896.85 |
| 合同负债 | 23,048,399.13 | 29,749,589.94 | 23,067,265.71 | 29,801,641.01 |
| 应付职工薪酬 | 3,220,737.51 | 7,812,287.88 | 5,585,655.38 | 3,323,820.8 |
| 应交税费 | 1,167,329.36 | 889,292.93 | 4,949,502.2 | 2,861,405.84 |
| 其他应付款合计 | 2,347,846 | 2,583,065.73 | 2,369,590.68 | 2,013,549.91 |
| 一年内到期的非流动负债 | 564,590.13 | 554,997.68 | 537,376.89 | 528,349.13 |
| 其他流动负债 | 438,541.54 | 704,237.74 | 503,767.99 | 660,799.23 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 114,482,878.12 | 108,233,580.73 | 162,524,484.69 | 153,949,212.77 |
| 非流动负债: | | | | |
| 租赁负债 | 963,058.81 | 1,105,969.58 | 1,218,069.03 | 1,355,072.89 |
| 递延收益 | 9,267,508.58 | 9,873,694.84 | 10,578,221.8 | 11,163,344.87 |
| 递延所得税负债 | 227,885.89 | 96,554.24 | 15,864.39 | 444,071.47 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 10,458,453.28 | 11,076,218.66 | 11,812,155.22 | 12,962,489.23 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 124,941,331.4 | 119,309,799.39 | 174,336,639.91 | 166,911,702 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 273,350,000 | 273,350,000 | 273,350,000 | 273,350,000 |
| 资本公积 | 222,590,227.52 | 222,590,227.52 | 222,590,227.52 | 222,590,227.52 |
| 减:库存股 | 28,821,193.58 | 28,821,193.58 | 28,821,193.58 | 28,652,380.11 |
| 盈余公积 | 64,918,823.11 | 64,918,823.11 | 59,114,149.94 | 59,114,149.94 |
| 未分配利润 | 144,886,819.78 | 136,512,308.27 | 141,984,611.02 | 124,038,023.2 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 676,924,676.83 | 668,550,165.32 | 668,217,794.9 | 650,440,020.55 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 676,924,676.83 | 668,550,165.32 | 668,217,794.9 | 650,440,020.55 |
| 负债和股东权益合计 | 801,866,008.23 | 787,859,964.71 | 842,554,434.81 | 817,351,722.55 |
| 公告日期 | 2024-04-29 | 2024-04-29 | 2023-10-26 | 2023-08-08 |
| 审计意见(境内) | | 标准无保留意见 | | |